Carter's Growth Story Gains Strength: Is More Upside Ahead?
CRI's recovery gains strength as sales growth, retail momentum and digital investments support improving execution and a stronger growth trajectory.
CRI - Carter's Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$40.33
DETAILS
HIGH:
$42.00
LOW:
$38.00
MEDIAN:
$41.00
CONSENSUS:
$40.33
UPSIDE:
20.21%
Stock News
Brokerages Set Carter’s, Inc. (NYSE:CRI) Price Target at $41.17
Carter's, Inc. (NYSE: CRI - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has
Carter's highlighted as Zacks Bull and Agnico Eagle Bear of the Day
Chicago, IL – August 26, 2026 – Zacks Equity Research shares Carter's CRI as the Bull of the Day and Agnico Eagle Mines AEM as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Rocket Companies' RKT, UWM Holdings Corp. UWMC and PennyMac Financial Services, Inc. PFSI.
Carter's (CRI) Loses 11.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Carter's (CRI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
New Strong Buy Stocks for August 24th
FHI, NVT, NESR, CRD.B and CRI have been added to the Zacks Rank #1 (Strong Buy) List on August 24th, 2026.
Best Income Stocks to Buy for August 24th
CURI, CRI and CRD.B made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 24th, 2026.
Carter's (CRI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Carter's (CRI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Are Investors Undervaluing Carter's (CRI) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Carter's, Inc. Announces Quarterly Dividend
ATLANTA--(BUSINESS WIRE)--The Board of Directors of Carter's, Inc. (NYSE:CRI) today declared a quarterly dividend of $0.25 per share, payable on September 25, 2026, to shareholders of record at the close of business on September 1, 2026. Future declarations of quarterly dividends and the establishment of future record and payment dates will be at the discretion of the Company's Board of Directors based on a number of factors, including business conditions, the Company's future financial perform.
Zacks Industry Outlook adidas, Steven, Wolverine, Carter's and Caleres
adidas, Steven, Wolverine, Carter's and Caleres have been highlighted in this Industry Outlook article.
Carter's Stock Surges 52% in a Year: Is It Time to Buy or Wait?
CRI's rally reflects stronger sales momentum and a consumer-led strategy, while digital investments and cost savings support growth.
5 Shoes & Retail Apparel Stocks to Watch as Demand & Innovation Accelerate
The Shoes & Retail Apparel industry players stand to benefit as premiumization, performance innovation and digital expansion reshape demand. Stocks like ADDYY, SHOO, WWW, CRI and CAL are positioned for growth.
Carter's (CRI) Is Up 3.60% in One Week: What You Should Know
Does Carter's (CRI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Carter's Gains 19.4% in 3 Months as Growth Momentum Supports Upside Case
CRI Q2 beat estimates as retail, e-commerce and international growth gained momentum, while tariffs remain a key risk to margins.
Is CRI a Buy After Growth Gains Despite Retail Risks Ahead?
Carter's Q2 momentum and raised outlook strengthen its recovery case, but tariff uncertainty, pricing pressure and consumer risks remain key concerns.
CRI Earnings Beat Raises Questions on Tariff Recovery and Growth Trend
Carter's Q2 beat estimates on retail, wholesale and productivity gains, but tariff recoveries and softer demand cloud the recovery outlook.
Should Value Investors Buy Carter's (CRI) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Carter's Q2 Earnings Beat Estimates on Wholesale and Retail Gains
CRI's Q2 earnings and sales top estimates as wholesale and retail gains offset tariff-driven gross-margin pressure.
Carter's Q2 Earnings Call Highlights
Carter's NYSE: CRI reported second-quarter fiscal 2026 results that exceeded its prior outlook, with net sales rising 5% from a year earlier to $615 million and adjusted operating income increasing 54% to $18 million. The company also narrowed its full-year sales outlook while maintaining its forecast for low- to mid-single-digit adjusted operating-income growth.
Carter's, Inc. (CRI) Q2 2026 Earnings Call Transcript
Carter's, Inc. (CRI) Q2 2026 Earnings Call Transcript
Price Targets
Carter's upgraded to Equal Weight from Underweight at Wells Fargo
$42.00
(was $41.10)
Wells Fargo
Carter's price target raised to $41 from $40 at UBS
$41.00
(was $35.33)
UBS
Carter's price target raised to $33 from $28 at Wells Fargo
$33.00
(was $37.57)
Wells Fargo
Carter's upgraded to Neutral from Sell at Goldman Sachs
$38.00
(was $36.79)
Goldman Sachs
Carter's price target raised to $40 from $33 at UBS
$40.00
(was $41.60)
UBS
Carter's price target raised to $29 from $26 at Goldman Sachs
$29.00
(was $35.63)
Goldman Sachs
Carter's initiated with a Sell at Goldman Sachs
$26.00
(was $33.35)
Goldman Sachs
Carter's price target raised to $33 from $26 at UBS
$33.00
(was $32.50)
UBS
Carter's price target raised to $25 from $22 at Wells Fargo
$25.00
(was $32.51)
Wells Fargo
Carter's price target raised to $26 from $23 at Barclays
$26.00
(was $32.98)
Barclays
Carter's price target raised to $23 from $22 at Barclays
$23.00
(was $29.74)
Barclays
Carter's initiated with an Underweight at Barclays
$25.00
(was $33.87)
Paul Kearney
·
Barclays
Carter's (CRI) PT Lowered to $60 at Evercore ISI
$60.00
(was $57.26)
Warren Cheng
·
Evercore ISI
CFRA Upgrades Carter's (CRI) to Buy
$84.00
(was $70.01)
Zachary Warring
·
CFRA